Market Place
Sourcing Support
Intellia Therapeutics Grants Inducements Under Nasdaq Listing
01 Aug 2025 //
GLOBENEWSWIRE
Intellia Therapeutics` Q2 2025 Earnings & Updates Conference Call
31 Jul 2025 //
GLOBENEWSWIRE
Intellia Therapeutics: Positive Three-Year Data on Lonvo-z in HAE
15 Jun 2025 //
GLOBENEWSWIRE
Intellia Reports Inducement Grants under Nasdaq LR 5635(c)(4)
05 Jun 2025 //
GLOBENEWSWIRE
Intellia Therapeutics Q1 2025 Financial Results and Progress
08 May 2025 //
GLOBENEWSWIRE
Intellia Therapeutics to Discuss First Quarter 2025 Earnings
01 May 2025 //
GLOBENEWSWIRE
Intellia Therapeutics: FDA grants RMAT to Nexiguran Ziclumeran
26 Mar 2025 //
GLOBENEWSWIRE
Intellia cuts 27% of staff as it takes ax to pipeline
10 Jan 2025 //
FIERCE BIOTECH
Intellia Reports Inducement Grants under Nasdaq LR 5635(c)(4)
05 Nov 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Reports Inducement Grants under Nasdaq Rule 5635(c)(4)
03 Sep 2024 //
GLOBENEWSWIRE
Intellia Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
24 Jul 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Announces CFO Transition
26 Jun 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Names Brian Goff to its Board of Directors
14 Jun 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Q1 2024 Results And Company Highlights
09 May 2024 //
GLOBENEWSWIRE
Intellia to Present NTLA-2002 Updates in HAE at EAACI 2024
29 Apr 2024 //
GLOBENEWSWIRE
Is Intellia Therapeutics Stock a Buy Now
08 Mar 2024 //
FOOL
Intellia Therapeutics Announces Q4 & Full-Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration
15 Feb 2024 //
PRESS RELEASE
Intellia Therapeutics cuts 15% of workforce, extends cash runway into mid-2026
05 Jan 2024 //
ENDPTS
Intellia Therapeutics Inc (NTLA): An Important Analyst Insights
14 Dec 2023 //
STOCK REGISTER
Intellia Therapeutics to Present Data from Ongoing Phase 1 Study of NTLA-2001
26 Oct 2023 //
GLOBENEWSWIRE
Intellia Therapeutics Receives PRIME Designation From EMA for NTLA-2002
13 Oct 2023 //
GLOBENEWSWIRE
Intellia Therapeutics Announces Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Intellia Therapeutics to Hold Conference to Discuss Second Quarter 2023 Earnings
27 Jul 2023 //
GLOBENEWSWIRE
Intellia Announces Retirement of Jean-Fran§ois Formela From Board of Directors
05 Jun 2023 //
GLOBENEWSWIRE
Intellia Therapeutics Announces 1Q 2023 FYR & Highlights Recent Company Progress
04 May 2023 //
GLOBENEWSWIRE
Intellia Releases 2023 Corporate Responsibility Report Highlighting
01 May 2023 //
GLOBENEWSWIRE
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023
27 Apr 2023 //
GLOBENEWSWIRE
Intellia Therapeutics Names Bill Chase to its Board of Directors
17 Apr 2023 //
GLOBENEWSWIRE
Intellia Therapeutics Announces FDA RMAT Designation Granted to NTLA-2002
21 Mar 2023 //
GLOBENEWSWIRE
Intellia Announces Fourth Quarter and Full-Year 2022 Financial Results
23 Feb 2023 //
GLOBENEWSWIRE
Intellia Therapeutics to Hold Conference to Discuss Fourth Quarter 2022 Earnings
16 Feb 2023 //
GLOBENEWSWIRE
Will Intellia Therapeutics Stock Rebound After A 31% Fall In A Month?
19 Dec 2022 //
FORBES
Intellia and Iveric sell stocks to raise money, each netting $300M
01 Dec 2022 //
ENDPTS
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
30 Nov 2022 //
GLOBENEWSWIRE
Intellia says CRISPR candidate may offer `functional cure` for HAE
15 Nov 2022 //
PRESS RELEASE
Intellia Presents New Interim Data from First-in-Human Study of NTLA-2002
14 Nov 2022 //
GLOBENEWSWIRE
Intellia CEO claims HAE gene editing treatment `may be a functional cure`
14 Nov 2022 //
ENDPTS
Intellia Presents Updated Interim Data from Cardiomyopathy of Ph1 of NTLA-2001
05 Nov 2022 //
GLOBENEWSWIRE
Intellia Therapeutics Announces Third Quarter 2022 Financial Results
03 Nov 2022 //
GLOBENEWSWIRE
Intellia Therapeutics to Present Data from Ongoing Phase 1/2 Study of NTLA-2002
31 Oct 2022 //
GLOBENEWSWIRE
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022
27 Oct 2022 //
PRESS RELEASE
3 Cathie Wood Stocks to Buy and Hold for 10 Years
19 Oct 2022 //
FOOL
Intellia Therapeutics: Top Speculative Trade In The Biotech Space
04 Oct 2022 //
SEEKING ALPHA
Intellia Therapeutics to Present at October Healthcare Investor Conferences
26 Sep 2022 //
GLOBENEWSWIRE
2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years
19 Sep 2022 //
FOOL
Intellia, Regeneron report positive initial data from phase 1 study of NTLA-2001
19 Sep 2022 //
PHARMABIZ
Intellia Announces Positive Data for CRISPR Candidate
17 Sep 2022 //
PRESS RELEASE
Intellia Investors Are Dumping Stock on News of Crispr Gene-Editing Success
16 Sep 2022 //
BARRONS
Intellia Announces Positive Interim Clinical Data for SecondCRISPR, NTLA-2002
16 Sep 2022 //
GLOBENEWSWIRE
Intellia Announces Upcoming Investor Event to NTLA-2002 and NTLA-2001
08 Sep 2022 //
GLOBENEWSWIRE
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002
01 Sep 2022 //
GLOBENEWSWIRE
Intellia to Present Interim Clinical Data from Phase 1/2 Study of NTLA-2002
23 Aug 2022 //
GLOBENEWSWIRE
Intellia amends polyneuropathy trial over enzyme level data
04 Aug 2022 //
FIERCEBIOTECH
Intellia Therapeutics Announces Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Intellia to Hold Conference Call to Discuss Q2 2022 Earnings and Company Updates
27 Jul 2022 //
GLOBENEWSWIRE
Intellia, Regeneron Present Interim Data from PI Study of NTLA-2001 for AATR
24 Jun 2022 //
PRNEWSWIRE
Novartis pays $75M to form sickle cell in vivo gene editing pact
22 Jun 2022 //
FIERCEBIOTECH
Intellia Tx to Present Updated Interim Data from Ongoing PI Study of NTLA-2001
08 Jun 2022 //
GLOBENEWSWIRE
Intellia Tx stocks falls for third straight session after Q1 earnings miss
09 May 2022 //
SEEKING ALPHA
